COVID-19 - March 8, 2023
PAD makes first investments
The partners in Pandemic Antiviral Discovery (PAD) initiative has announced grants totalling more than USD 26 million for 14 research projects aimed at facilitating early-stage development of drugs to treat henipavirus infection and disease in humans. These grants mark the majority of the first investments to come from the PAD initiative, a global philanthropic collaboration […]
COVID-19 - November 7, 2022
AstraZeneca’s Vaxzevria receives full Marketing Authorization in the EU
AstraZeneca’s COVID-19 vaccine, Vaxzevria, has been granted full Marketing Authorisation (MA) in the European Union (EU). Vaxzevria was originally granted a conditional Marketing Authorisation (cMA) due to the urgency of the COVID-19 pandemic. As there continues to be sufficient evidence of safety and efficacy confirming the benefits of Vaxzevria, the European Medicines Agency (EMA) has now granted a full […]
COVID-19 - September 21, 2022
AstraZeneca’s Evusheld approved in the EU
Evusheld, a long-acting antibody combination, has been approved in the European Union (EU) for the treatment of adults and adolescents with COVID-19 who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19. “COVID-19 remains an ongoing health concern for millions of Europeans and around the world, especially for […]
COVID-19 - August 24, 2022
Promising results from new generation of corona vaccine
Researchers at Karolinska Institutet are developing a coronavirus vaccine designed to be less sensitive to mutations and equipped for future strains. The vaccine showed promising results in mice in a newly published study in EMBO Molecular Medicine, and the researchers now hope to be able to take it to safety studies on humans. “This is […]
COVID-19 - June 29, 2022
Nordic COVID-19 studies provide new insight
Two ongoing research studies funded by NordForsk are providing new knowledge about COVID-19 related to pregnancy and mental health. The Nordic countries have similar welfare systems, access to high-quality health data, and publicly funded health services. Together with citizens’ trust in research, this all represents a particular strength in this context, describes NordForsk. Five collaborative […]
COVID-19 - June 21, 2022
Bavarian Nordic provides update on its COVID-19 booster vaccine candidate
Bavarian Nordic has provided an update on the Phase 3 development of ABNCoV2, a VLP-based, non-adjuvanted COVID-19 booster vaccine candidate. The upcoming Phase 3 trial has been redesigned to include a licensed mRNA-based vaccine (Comirnaty) in the comparator arm of the study, to potentially support the primary objective of the study and demonstrate that the […]
